Acquisition by Thompson Peter A. of 15000 shares of Corvus Pharmaceuticals at 2.6 subject to Rule 16b-3
| CRVS Stock | USD 8.24 0.16 1.90% |
Slightly above 62% of Corvus Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Corvus Pharmaceuticals stock suggests that many investors are alarmed at this time. Corvus Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Corvus Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Corvus |
Filed transaction by Corvus Pharmaceuticals Director, 10 Percent Owner . Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Corvus Pharmaceuticals Fundamental Analysis
We analyze Corvus Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Corvus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Corvus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Corvus Pharmaceuticals is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Corvus Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Corvus Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Corvus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Corvus Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Corvus Pharmaceuticals Related Equities
| MREO | Mereo BioPharma | 2.58 | ||||
| DAWN | Day One | 0.74 | ||||
| INZY | Inozyme Pharma | 0.71 | ||||
| ABOS | Acumen Pharmaceuticals | 0.84 | ||||
| HOOK | Hookipa Pharma | 2.51 | ||||
| PDSB | PDS Biotechnology | 3.33 | ||||
| TERN | Terns Pharmaceuticals | 5.25 | ||||
| XFOR | X4 Pharmaceuticals | 8.11 |
Additional Tools for Corvus Stock Analysis
When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.